Compare OOMA & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OOMA | HQL |
|---|---|---|
| Founded | 2003 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Investment Managers |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 548.1M | 539.1M |
| IPO Year | 2015 | N/A |
| Metric | OOMA | HQL |
|---|---|---|
| Price | $19.16 | $18.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $26.80 | N/A |
| AVG Volume (30 Days) | ★ 285.0K | 110.1K |
| Earning Date | 12-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | ★ 188.46 | N/A |
| EPS | 0.20 | ★ 0.79 |
| Revenue | ★ $114,490,000.00 | N/A |
| Revenue This Year | $21.68 | N/A |
| Revenue Next Year | $4.82 | N/A |
| P/E Ratio | $94.28 | ★ $22.90 |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $15.66 |
| 52 Week High | $26.19 | $22.67 |
| Indicator | OOMA | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 48.81 |
| Support Level | $16.42 | $16.78 |
| Resistance Level | $19.56 | $18.37 |
| Average True Range (ATR) | 0.67 | 0.49 |
| MACD | -0.02 | 0.16 |
| Stochastic Oscillator | 5.36 | 64.37 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.